



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 10, 2019: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**

- **Medical Director Update** **6:40 - 6:45**

- **Follow-up Items from Previous Meetings** **6:45 - 6:45**

- **RetroDUR/ProDUR** **6:45 - 7:15**
 - Introduce: Discussion Topics for 2020 RetroDUR Initiatives
 - Data Presentation: Use of Gabapentin

- **Clinical Update: Drug Reviews** **7:15-7:45**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - None at this time

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)
 - Apadaz® (benzhydrocodone and acetaminophen)
 - Firdapse® (amifampridine)
 - Gamifant® (emapalumab-lzsg)
 - Inbrija® (levodopa inhalation powder)
 - Lexette® (halobetasol propionate)
 - Motegrity® (prucalopride)
 - Nuzyra® (omadacycline)
 - Qbrexza® (glycopyrronium)
 - Seysara® (sarecycline tablets)
 - Spravato® (esketamine nasal spray)
 - Symjepi® (epinephrine)

- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:25**
(Public comment prior to Board action)
 - Androgenic Agents
 - Antiemetics
 - Antipsychotics
 - Bronchodilators: Beta Agonists
 - COPD Agents
 - Growth Hormones
 - Inhaled Glucocorticosteroids
 - PAH

- **Review of Newly-Developed/Revised Criteria** **8:25 - 8:25**
(Public comment prior to Board action)
 - None at this time

- **General Announcements** **8:25 – 8:30**
 - **Selected FDA Safety Alerts**
 - FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)
<https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and>

- **Adjourn** **8:30**